Induction of human cytotoxic T lymphocytes specific for prostate- specific antigen

Prostate

Volumn 30, Issue 2, 1997, Pages 73-78

  Xue, Bao Hua ^a   Zhang, Yong ^a   Sosman, Jeffrey A ^a   Peace, David J ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

class I major histocompatibility complex; HLA A2; immunotherapy; in vitro immunization; tumor antigen

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; HLA A2 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PROSTATE SPECIFIC ANTIGEN; SYNTHETIC PEPTIDE; TUMOR ANTIGEN;

AMINO ACID SEQUENCE; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; CANCER IMMUNOTHERAPY; CELL SPECIFICITY; CYTOTOXIC T LYMPHOCYTE; HLA SYSTEM; HUMAN; HUMAN CELL; MALE; PHENOTYPE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; T LYMPHOCYTE SUBPOPULATION;

ADENOCARCINOMA; EPITOPES; HLA-A2 ANTIGEN; HUMANS; IMMUNITY, CELLULAR; IMMUNIZATION; IMMUNOTHERAPY; MALE; PEPTIDE FRAGMENTS; PEPTIDES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 0031020088     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(19970201)30:2<73::AID-PROS1>3.0.CO;2-L     Document Type: Article

References (31)

1. Boring CC, Squires TS, Tong T, Montgomery S: Cancer statistics, 1994. CA 43:7-26, 1994.
2. Li TS, Beling CG: Isolation and characterization of two specific antigens of human seminal plasma. Fertil Steril 24:134-144, 1973.
3. Watt KWK, Lee PJ, M'TimKulu T, Chan WP, Loor R: Human prostate-specific antigen: Structural and functional similarity with gene proteases. Proc Natl Acad Sci USA 83:3166-3170, 1986.
4. Hara M, Koyanagi Y, Inoue T, Fukuyama T: Some physico-chemical characteristics of gamma-seminoprotein, an antigenic component for human seminal plasma. Jpn J Legal Med 25:322-324, 1971.
5. Oesterling JE: Prostate-specific antigen: A critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 145:907-923, 1991.
6. Ford TF, Butcher DN, Masters JRW, Parkinson MC: Immunocytochemical localization of prostate-specific antigen: Specificity and application to clinical practice. Br J Urol 57:50-55, 1985.
7. Townsend A, Bodmer H: Antigen recognition by class I-restricted T lymphocytes. Annu Rev Immunol 7:601-624, 1989.
8. Grey HM, Sette A, Buus S: How T cells see antigen. Sci Am 261:56-64, 1989.
9. Falk K, Rötzschke O, Stevanovic S, Jung G, Rammensee HG: Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 351:290-296, 1991.
10. Kubo RT, Sette A, Grey HM, Appella E, Sakaguchi K, Zhu N-Z, Arnott D, Sherman N, Shabanowitz J, Michel H, Bodnar W, Davis TA, Hunt DF: Definition of specific peptide motifs for four major HLA-A alleles. J Immunol 152:3913-3924, 1994.
11. Carbone F, Moore M, Sheil J, Bevan M: Induction of cytotoxic T lymphocytes by primary in vitro stimulation with peptides. J Exp Med 167:1767-1779, 1988.
12. Disis ML, Smith JW, Murphy AE, Chen W, Cheever MA: In vitro generation of human cytolytic T-cells specific for peptides derived from the HER-2/neu protooncogene protein. Cancer Res 54:1071-1076, 1994.
13. Houbiers JGA, Nijman HW, Burg SH van der, Drijfhout JW, Kenmans P, Velde CJH van der, Brand A, Momburg F, Kast WM, Melief CJM: In vitro induction of human cytotoxic T lymphocytes responses against peptides of mutant and wild-type p53. Eur J Immunol 23:2072-2077, 1993.
14. Celis E, Tsai V, Crimi C, DeMars R, Wentworth PA, Chestnut RW, Grey HM, Sette A, Serra HM: Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. Proc Natl Acad Sci USA 91:2105-2109, 1994.
15. Macatonia SE, Patterson S, Knight SC: Primary proliferative and cytotoxic T-cell responses to HIV induced in vitro by human dendritic cells. Immunology 74:399-406, 1991.
16. Baur MP, Danilovs JA: Population analysis of HLA-A, B, C, Dr and other genetic markers. In PI Terasaki (ed): "Histocompatibility Testing." Berlin: Springer-Verlag, 1980, p 955.
17. Lundwall A, Lilja H: Molecular cloning of human prostate specific antigen cDNA. FEBS Lett 214:317-322, 1987.
18. Salter RD, Cresswell P: Impaired assembly and transport of HLA-A and -B antigens in a TxB cell hybrid. EMBO J 5:943-949, 1986.
19. Peace DJ, Kern DE, Schultz KR, Greenberg PD, Cheever MA: Interleukin-4-induced lymphokine activated killer cells: Lytic activity is mediated by phenotypically distinct NK-like and T cell-like large granular lymphocytes. J Immunol 140:3679-3685, 1988.
20. Ruppert J, Sidney J, Celis E, Kubo RT, Grey HM, Sette A: Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. Cell 74:929-937, 1993.
21. Townsend A, Rothbard J, Frances M, Gotch G, Bahadur J, Wrath D, McMichael A: The epitopes of influenza nucleoproteins recognized by cytotoxic lymphocytes can be defined with short synthetic peptides. Cell 44:959-968, 1986.
22. Kast W, Brandt R, Drijfhout J, Melief C: Human leukocyte antigen-A2.1 restricted candidate cytotoxic T lymphocyte epitopes of human papillomavirus type 16 E6 and E7 proteins identified by using the processing-defective human cell line T2. J Immunother 14:115-120, 1993.
23. Parker K, Bednarek M, Hull L, Utz U, Cunningham B, Zweerink H, Biddison W, Coligan J: Sequence motifs important for peptide binding to the human MHC class I molecule HLA-A2. J Immunol 148:3580-3587, 1992.
24. + T cells binds very tightly to the restricting class I major histocompatibility complex protein on intact cells but not to the purified class I protein. Proc Natl Acad Sci USA 88:11276-11280, 1991.
25. Akdas A, Turkeri L, Alican Y, Simsek F, Akoglu T: Human leukocyte antigen subtype analysis in patients with advanced adenocarcinoma of the prostate. Prostate 24:111-113, 1994.
26. Parker KC, Bednarel MA, Coligan JE: Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 152:163-175, 1994.
27. Stauss HJ, Davies H, Sadovnikova E, Chain B, Horowitz N, Sinclair C: Induction of cytotoxic T lymphocytes with peptides in vitro: Identification of candidate T-cell epitopes in human papilloma virus. Proc Natl Acad Sci USA 89:7871-7875, 1992.
28. Riddell SR, Watanabe KS, Goodrich IM, Li CR, Agha ME, Greenberg PD: Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 257:238-241, 1992.
29. Sanda MG, Restifo NP, Walsh JC, Kawakami Y, Nelson WG, Pardoll DM, Simons JW: Molecular characterization of defective antigen processing in human prostate cancer. J Natl Cancer Inst 87:280-285, 1995.
30. Montgomery BT, Young CY-F, Bilhartz DL, Andrews PE, Prescott JL, Thompson NF, Tindall DJ: Hormonal regulation of prostate-specific antigen (PSA) glycoprotein in the human prostatic adenocarcinoma cell line, LNCaP. Prostate 21:63-73, 1992.
31. Monne M, Croce CM, Yu H, Diamandis EP: Molecular characterization of prostate-specific antigen messenger RNA expressed in breast tumors. Cancer Res 54:6344-6347, 1994.